Answers are grounded in this paper and cite their sources.
Evidence reports deucravacitinib provides lasting disease control in patients with moderate-to-severe psoriasis, indicating its reliability as a treatment option.
Long-term evidence affirms deucravacitinib’s durable disease control, stable safety, and patient-friendly convenience. With once-daily oral dosing, minimal laboratory monitoring, and efficacy across difficult-to-treat sites, deucravacitinib represents a practical and reliable long-term therapy with oral simplicity for patients with moderate-to-severe plaque psoriasis. J Drugs Dermatol. 2026;25:2(Suppl 1):s3-s10.
No takes yet. Share an insight, caveat, or question.
Katz et al. (2026) studied this question.